
    
      Patients undergoing elective catheter ablation for symptomatic PAF who are refractory or
      intolerant to at least one antiarrhythmic drug (Class I-IV) will be screened for enrollment.
      Patients who meet the study entry criteria and sign the patient informed consent form will be
      enrolled and treated consistent with the 2012 Heart Rhythm Society (HRS)/European Heart
      Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Expert Consensus
      Statement on Catheter and Surgical Ablation for Atrial Fibrillation. Eligible patients will
      receive treatment with the VAS including ultrasound imaging of the left atrium and cardiac
      ablation to electrically isolate the pulmonary veins.

      Up to 100 patients will be enrolled at up to 10 sites in Europe (EU) and in the United States
      (US).
    
  